-
| Exchange | PINK |
|---|---|
| CurrencyCode | USD |
| ISIN | US53000N1081 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Dividend Yield | 0.0% |
|---|---|
| Market Cap | 10M |
| Target Price | 4.8 |
| PE Ratio | None |
| Beta | 0.42 |
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LIANY using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026